Evidence map›Paper›PMID 10339585›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1999

Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.

G X Cheng, X H Zhu, X Q Men, L Wang, Q H Huang, X L Jin, S M Xiong, J Zhu, W M Guo, J Q Chen and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 91 citations in OpenAlex.

  1. Trial
  2. Review
  3. [The cure for acute promyelocytic leukemia and China's contributions].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Murine Models of Acute Myeloid Leukaemia.International journal of molecular sciences · 2019
    Review
  9. Review
  10. RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  11. Article
  12. Article
  13. Article
  14. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.Mediterranean journal of hematology and infectious diseases · 2011
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 2 countries.

G X ChengResearch Center for Transgenic Animals, College of Livestock and Veterinary, Yangzhou University, Yangzhou, People's Republic of China. chenggx@lvyuan.net.cn
X H Zhu
X Q Men
L Wang
Q H Huang
X L Jin
S M Xiong
J Zhu
W M Guo
J Q Chen
S F Xu
E So
L C Chan
S Waxman
A Zelent
G Q Chen
S Dong
J X Liu
S J Chen
Shanghai Institute of Hematology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is characterized by a specific chromosome translocation involving RARalpha and one of four fusion partners: PML, PLZF, NPM, and NuMA genes. To study the leukemogenic potential of the fusion genes in vivo, we generated transgenic mice with PLZF-RARalpha and NPM-RARalpha. PLZF-RARalpha transgenic animals developed chronic myeloid leukemia-like phenotypes at an early stage of life (within 3 months in five of six mice), whereas three NPM-RARalpha transgenic mice showed a spectrum of phenotypes from typical APL to chronic myeloid leukemia relatively late in life (from 12 to 15 months). In contrast to bone marrow cells from PLZF-RARalpha transgenic mice, those from NPM-RARalpha transgenic mice could be induced to differentiate by all-trans-retinoic acid (ATRA). We also studied RARE binding properties and interactions between nuclear corepressor SMRT and various fusion proteins in response to ATRA. Dissociation of SMRT from different receptors was observed at ATRA concentrations of 0.01 microM, 0.1 microM, and 1.0 microM for RARalpha-RXRalpha, NPM-RARalpha, and PML-RARalpha, respectively, but not observed for PLZF-RARalpha even in the presence of 10 microM ATRA. We also determined the expression of the tissue factor gene in transgenic mice, which was detected only in bone marrow cells of mice expressing the fusion genes. These data clearly establish the leukemogenic role of PLZF-RARalpha and NPM-RARalpha and the importance of fusion receptor/corepressor interactions in the pathogenesis as well as in determining different clinical phenotypes of APL.

Indexed as

AnimalsAntigens, NuclearBone Marrow CellsCell Cycle ProteinsCell DifferentiationChorionic GonadotropinDNA-Binding ProteinsGrowthHumansKruppel-Like Transcription FactorsLeukemia, Promyelocytic, AcuteMiceMice, TransgenicNuclear Matrix-Associated ProteinsNuclear ProteinsOncogene Proteins, FusionAntigens, NuclearCell Cycle ProteinsChorionic GonadotropinDNA-Binding ProteinsKruppel-Like Transcription FactorsNuclear Matrix-Associated ProteinsNuclear ProteinsNUMA1 protein, humanNuma1 protein, mouseOncogene Proteins, FusionPromyelocytic Leukemia Zinc Finger ProteinRARA protein, humanRara protein, mouseReceptors, Retinoic AcidRetinoic Acid Receptor alphaTranscription FactorsTretinoinZBTB16 protein, humanZbtb16 protein, mouse

Identifiers

PMID10339585
PMCPMC26879
OpenAlexW2011636814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.